ArticleJournal of cancer research and clinical oncology2025
EYA1 promotes tumor angiogenesis in colorectal cancer by activating HIF-1β through LSD2-mediated H3K4me2 demethylation.
Article in Journal of cancer research and clinical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundColorectal cancer (CRC) is one of the most common cancers worldwide, with tumor angiogenesis playing a crucial role in its progression. The Drosophila Eyes Absent Homologue 1(Eya1) has been implicated in various cancers, but its mechanism in CRC angiogenesis remains unclear. This study explores the mechanism by which Eya1 regulates angiogenesis in CRC by activating HIF-1β through Lysine-specific demethylases 2 (LSD2).
methodsCRC tissues and cell lines were analyzed to assess Eya1 and LSD2 using qPCR and Western blot. VEGFA expression and endothelial cell proliferation were measured using ELISA and tube formation assays. Co-immunoprecipitation (Co-IP) and chromatin immunoprecipitation (ChIP) assays were used to investigate protein interactions and histone modifications.
resultsWe found that Eya1 and LSD2 were significantly upregulated in CRC tissues and cell lines. Eya1 overexpression increased VEGFA expression and promoted endothelial cell proliferation and tube formation, and the effects were abolished upon silencing LSD2 or HIF-1β. Additionally, Eya1 was shown to interact with Dach1, a co-stimulatory factor, to regulate LSD2 expression and its activity in promoting HIF-1β-mediated angiogenesis.
conclusionThis study demonstrates that Eya1 promotes CRC angiogenesis through the LSD2/HIF-1β/VEGF pathway. These findings identify a novel mechanism of angiogenesis regulation in CRC, suggesting that targeting the Eya1-LSD2-HIF-1β axis may provide new therapeutic strategies for CRC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.